13D Filing: Perceptive Advisors Keeps Funding Vbi Vaccines Inc

“On December 13, 2018, the Fund purchased 14,285,714 shares of Common Stock at a price of $1.40 per share,” The details of the filing can be seen below:

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Perceptive Advisors 0 25,700,263 0 25,700,263 25,700,263 27.6%
Joseph Edelman 0 25,700,263 0 25,700,263 25,700,263 27.6%
Perceptive Life Sciences Master Fund, Ltd 0 23,631,439 0 23,631,439 23,631,439 25.3%
Perceptive Credit Holdings 0 2,068,824 0 2,068,824 2,068,824 2.2%

Follow Joseph Edelman's Perceptive Advisors

Page 1 of 7 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

VBI Vaccines
Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

91822J 10 3

(CUSIP
Number)

Alexander Rakitin

Perceptive Advisors LLC

51 Astor Place, 10th Floor

New York, NY 10003

(646)
205-5340

(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)

December 13, 2018

(Date of Event Which Requires Filing of this Statement)

If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13D-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information
required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Vbi Vaccines Inc (NASDAQ:VBIV)

Page 2 of 7 – SEC Filing


CUSIP No.    91822J 10 3
  (1)

Name of
reporting persons

Perceptive Advisors LLC

  (2)

Check the appropriate box if a member
of a group

(a)  ☐        (b)  ☒

  (3)

SEC use only

  (4)

Source of funds

AF

  (5)

Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)

  (6)

Citizenship or place of
organization

Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

  (7)

Sole voting power

0

  (8)

Shared voting power

25,700,263

  (9)

Sole dispositive power

0

(10)

Shared dispositive power

25,700,263

(11)

Aggregate amount beneficially owned by each reporting person

25,700,263

(12)

Check box if the aggregate amount in
Row (11) excludes certain shares*

(13)

Percent of class represented by amount
in Row (11)

27.6%

(14)

Type of reporting person

IA

Follow Vbi Vaccines Inc (NASDAQ:VBIV)

Page 3 of 7 – SEC Filing


CUSIP No.    91822J 10 3
  (1)

Name of
reporting persons

Joseph Edelman

  (2)

Check the appropriate box if a member
of a group

(a)  ☐        (b)  ☒

  (3)

SEC use only

  (4)

Source of funds

AF

  (5)

Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)

  (6)

Citizenship or place of
organization

United States of America

Number of

shares

beneficially

owned by

each

reporting

person

with

  (7)

Sole voting power

0

  (8)

Shared voting power

25,700,263

  (9)

Sole dispositive power

0

(10)

Shared dispositive power

25,700,263

(11)

Aggregate amount beneficially owned by each reporting person

25,700,263

(12)

Check box if the aggregate amount in
Row (11) excludes certain shares*

(13)

Percent of class represented by amount
in Row (11)

27.6%

(14)

Type of reporting person

IN

Follow Vbi Vaccines Inc (NASDAQ:VBIV)

Page 4 of 7 – SEC Filing


CUSIP No.    91822J 10 3
  (1)

Name of
reporting persons

Perceptive Life Sciences Master Fund, Ltd.

  (2)

Check the appropriate box if a member
of a group

(a)  ☐        (b)  ☒

  (3)

SEC use only

  (4)

Source of funds

WC

  (5)

Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)

  (6)

Citizenship or place of
organization

Cayman Islands

Number of

shares

beneficially

owned by

each

reporting

person

with

  (7)

Sole voting power

0

  (8)

Shared voting power

23,631,439

  (9)

Sole dispositive power

0

(10)

Shared dispositive power

23,631,439

(11)

Aggregate amount beneficially owned by each reporting person

23,631,439

(12)

Check box if the aggregate amount in
Row (11) excludes certain shares*

(13)

Percent of class represented by amount
in Row (11)

25.3%

(14)

Type of reporting person

CO

Follow Vbi Vaccines Inc (NASDAQ:VBIV)

Page 5 of 7 – SEC Filing


CUSIP No.    91822J 10 3
  (1)

Name of
reporting persons

Perceptive Credit Holdings, LP

  (2)

Check the appropriate box if a member
of a group

(a)  ☐        (b)  ☒

  (3)

SEC use only

  (4)

Source of funds

WC

  (5)

Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)

  (6)

Citizenship or place of
organization

Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

  (7)

Sole voting power

0

  (8)

Shared voting power

2,068,824

  (9)

Sole dispositive power

0

(10)

Shared dispositive power

2,068,824

(11)

Aggregate amount beneficially owned by each reporting person

2,068,824

(12)

Check box if the aggregate amount in
Row (11) excludes certain shares*

(13)

Percent of class represented by amount
in Row (11)

2.2%

(14)

Type of reporting person

PN

Follow Vbi Vaccines Inc (NASDAQ:VBIV)

Page 6 of 7 – SEC Filing


CUSIP No. 91822J 10 3

Item 3 Source and Amount of Funds or Other Consideration.

Item 3 is amended and supplemented as follows:

The Fund purchased the shares of Common Stock described in Item 5(c) using funds from working capital.

Item 5 Interest in Securities of the Issuer.

Item 5 is amended and restated as follows:

(a)-(b) The information required by this item with respect to each Reporting Person is set forth in Rows 7 through 11 and 13 of each cover page
to this Schedule 13D. The ownership percentages reported are based on 91,183,391 outstanding shares of Common Stock as disclosed in the Issuers prospectus supplement filed on December 17, 2018.

The Fund directly holds 23,631,439 shares of Common Stock. The Credit Fund directly holds 2,068,824 warrants each exercisable for one share of
Common Stock. The Investment Manager serves as the investment manager to the Fund and the Credit Fund and may be deemed to beneficially own the securities directly held by the Fund and the Credit Fund. Mr. Edelman is the managing member of the
Investment Manager and may be deemed to beneficially own the securities directly held by the Master Fund and the Credit Fund.

(c) On
December 13, 2018, the Fund purchased 14,285,714 shares of Common Stock at a price of $1.40 per share.

(d)-(e) Not applicable

Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of the Original Schedule 13D is hereby amended to add the following:

Lock-Up Agreement

In connection with the Issuers registered public offering, the Reporting Persons have agreed, with certain limited exceptions, including distributions to
limited partners and transfers to affiliates, which in each case would be subject to the recipient signing a similar lock-up agreement, not to directly or indirectly: (i) sell, offer, contract or grant
any option to sell (including any short sale), pledge, transfer, establish an open put equivalent position within the meaning of Rule 16a-l(h) under the Securities Exchange Act of 1934, as amended,
or otherwise dispose of any Common Stock or other equity securities of the Issuer, (ii) enter into any swap, hedge or other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of any Common Stock
or other equity securities of the Issuer, (iii) request or demand that the Issuer publicly file a registration statement related to the Common Stock, or (iv) publicly announce an intention to do any of the foregoing, in each case for a
period of 90 days from the date of the underwriting agreement for the Issuers registered offering, without the prior written consent of the representatives.

Follow Vbi Vaccines Inc (NASDAQ:VBIV)

Page 7 of 7 – SEC Filing


SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this
statement is true, complete and correct.

Date: December 17, 2018
PERCEPTIVE ADVISORS LLC
By:

/s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member

/s/ Joseph
Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC
By:

/s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member

PERCEPTIVE CREDIT HOLDINGS, LP

By: Perceptive Advisors LLC
By:

/s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member

Follow Vbi Vaccines Inc (NASDAQ:VBIV)